跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Xolair 150mg Powder and Solvent for Solution for Injection - HSA Drug Approval Details
Approvals
/
HSA
/
Xolair 150mg Powder and Solvent for Solution for Injection
Approved
THERAPEUTIC
Xolair 150mg Powder and Solvent for Solution for Injection
Takeda Austria GmbH (AUSTRIA)Novartis Pharma Stein AG (SWITZERLAND)DELPHARM DIJON - QUETIGNY (FRANCE)
🇸🇬 Health Sciences Authority
Approval Date
Jul 7, 2006
Approval ID
bc401b03110fd46e
Company
Takeda Austria GmbH (AUSTRIA)Novartis Pharma Stein AG (SWITZERLAND)DELPHARM DIJON - QUETIGNY (FRANCE)
Type
Therapeutic
Approval Details
Approval Id
bc401b03110fd46e
Drug Name
Xolair 150mg Powder and Solvent for Solution for Injection
Product Name
Xolair 150mg Powder and Solvent for Solution for Injection
Approval Number
SIN13212P
Approval Date
2006-07-07
Registrant
NOVARTIS (SINGAPORE) PTE LTD
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route Of Administration
SUBCUTANEOUS
Atc Code
R03DX05
Atc Item Name
omalizumab
Pharma Manufacturer Name
NOVARTIS (SINGAPORE) PTE LTD
Active Ingredients
Omalizumab
150mg
Omalizumab
150mg
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Jul 7, 2006
Approval ID
bc401b03110fd46e
Type
Therapeutic
Back to HSA Approvals
